IMNM
Immunome, Inc.
Stock
$20.90+0.01 (+0.05%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$209M | −$191M | −$111M | −$7.6M | −$29M | −$18M | −$12M | −$9.6M |
| Capital expenditures | $10M | $9.7M | $7.2M | $831K | $248K | $79K | $586K | $233K |
| Free cash flow | −$219M | −$201M | −$118M | −$8.4M | −$29M | −$18M | −$13M | −$9.8M |
| Stock-based compensation | $31M | $26M | $16M | $6.2M | $5.3M | $3.4M | $621K | $14K |
| Free cash flow margin | — | −2,890.1% | −1,304.8% | −59.9% | — | — | — | — |